Pharvaris N.V.
PHVS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001830487
In the last 90 days, Pharvaris N.V. insiders filed 0 open-market purchases and 18 sales; 125 institutions reported holding it in 13F filings for Q2 2026, worth $2.23B in total; Viking Global Investors is the only superinvestor holding it.
13F holders, Q3 2023
Institutional positions in Pharvaris N.V. as of Sep 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 21
- 0 vs. Q2 2023
- Shares held
- 29.1M
- +153.3K (+0.5%) vs. Q2 2023
- Total value
- $606.6M
- +$165.1M (+37.4%) vs. Q2 2023
- New holders
- 3
- 6 more added
- Sold out
- 3
- 6 more reduced
Compare with Q2 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting PHVS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 125 | $2.23B |
| Q1 2026 | 110 | $1.67B |
| Q4 2025 | 106 | $1.64B |
| Q3 2025 | 83 | $1.44B |
| Q2 2025 | 60 | $792.7M |
| Q1 2025 | 52 | $705.5M |
| Q4 2024 | 54 | $855.8M |
| Q3 2024 | 51 | $834.2M |
| Q2 2024 | 36 | $808.6M |
| Q1 2024 | 35 | $980.5M |
| Q4 2023 | 36 | $1.14B |
| Q3 2023 | 21 | $606.6M |
| Q2 2023 | 21 | $441.6M |
| Q1 2023 | 21 | $173.9M |
| Q4 2022 | 25 | $239.6M |
| Q3 2022 | 21 | $173.6M |
| Q2 2022 | 20 | $494.0M |
| Q1 2022 | 22 | $397.1M |
| Q4 2021 | 22 | $321.1M |
| Q3 2021 | 25 | $380.3M |
| Q2 2021 | 28 | $406.3M |
| Q1 2021 | 33 | $616.5M |
Institutions, Q3 2023
Shares, value and share of portfolio for each institution holding Pharvaris N.V.; share changes are against Q2 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| UBS Group AG | 50 | $1.04K | 0.00% | −1,250−96.2% | Reduced |
| BlackRock Inc. | 2,268 | $47.3K | 0.00% | +2,112+1,353.8% | Added |
| Qube Research & Technologies Ltd | 2,579 | $53.8K | 0.00% | +2,579 | New |
| Schonfeld Strategic Advisors LLC | 11,900 | $248.4K | 0.00% | +300+2.6% | Added |
| Y-Intercept (Hong Kong) Ltd | 17,553 | $366.3K | 0.04% | +17,553 | New |
| Geode Capital Management, LLC | 21,595 | $450.7K | 0.00% | +2,952+15.8% | Added |
| Foresite Capital Management V, LLC | 33,142 | $691.7K | 1.10% | −1,000−2.9% | Reduced |
| Morgan Stanley | 33,697 | $703.3K | 0.00% | −11,635−25.7% | Reduced |
| Hudson Bay Capital Management LP | 38,893 | $811.7K | 0.01% | +38,893 | New |
| Walleye Capital LLC | 81,017 | $1.69M | 0.02% | +10,691+15.2% | Added |
| Soleus Capital Management, L.P. | 343,975 | $7.18M | 0.72% | −47,925−12.2% | Reduced |
| 5AM Venture Management, LLC | 587,600 | $12.3M | 3.53% | 00.0% | Unchanged |
| Novo Holdings A/S | 1,329,325 | $27.7M | 2.05% | 00.0% | Unchanged |
| Cormorant Asset Management, LP | 1,361,460 | $28.4M | 1.66% | +387,846+39.8% | Added |
| VR Adviser, LLC | 1,563,513 | $32.6M | 3.43% | +237,313+17.9% | Added |
| FMR LLC | 3,207,564 | $66.9M | 0.01% | −179,593−5.3% | Reduced |
| Viking Global Investors LPSuperinvestorViking Global Investors | 3,231,923 | $67.5M | 0.27% | 00.0% | Unchanged |
| Foresite Capital Management IV, LLC | 3,743,450 | $78.1M | 43.39% | 00.0% | Unchanged |
| venBio Partners LLC | 4,264,672 | $89.0M | 25.24% | 00.0% | Unchanged |
| General Atlantic LLC | 4,406,252 | $92.0M | 1.42% | 00.0% | Unchanged |
| Bain Capital Life Sciences Investors, LLC | 4,784,674 | $99.9M | 11.17% | −84,110−1.7% | Reduced |
| Silverarc Capital Management, LLC | 0 | $0 | 0.00% | −200,000−100.0% | Sold out |
| Lynx1 Capital Management LP | 0 | $0 | 0.00% | −21,225−100.0% | Sold out |
| JPMorgan Chase & Co | 0 | $0 | 0.00% | −151−100.0% | Sold out |